肝细胞癌放射治疗联合系统治疗的研究进展

摘要/Abstract

摘要： 肝细胞癌（hepatocellular carcinoma,HCC）是世界范围内癌症死亡的主要原因,是我国最常见的恶性肿瘤之一。目前早期HCC患者多采用外科手术治疗,但大多数HCC患者确诊时已处于中晚期,丧失手术机会。随着放射治疗技术的进步及治疗靶点的发现,HCC使用放射治疗联合系统治疗的机会迅速增加,并在临床得到推广。本文对HCC放射治疗联合系统治疗的研究进展进行综述,以期探究有效的放射治疗联合系统治疗的方案,以改善HCC患者症状及预后。

关键词: 肝细胞癌, 放射治疗, 系统治疗

Abstract: Hepatocellular carcinoma (HCC) is the leading cause of cancer death in the world and one of the most common malignant tumors in China. At present, a small percentage of patients with early-stage disease is mostly treated by surgery. However, most patients are in the middle and late stage when diagnosed, and lose the opportunity of surgery. With the progress of radiotherapy methods and the discovery of therapeutic targets, the comprehensive treatment of HCC using radiotherapy combined with systemic therapy has rapidly increased, which are also popularized in clinical practice. In order to explore effective radiotherapy combined with systemic therapy and improve the condition and prognosis of patients with HCC, this review will systematically introduce the research progress of radiotherapy combined with systemic therapy for HCC.

Key words: Hepatocellular carcinoma, Radiotherapy, Systemic therapy

李长英, 许新, 邓敏. 肝细胞癌放射治疗联合系统治疗的研究进展[J]. 肝癌电子杂志, 2022, 9(4): 15-19.

Li Changying, Xu Xin, Deng Min^*. Radiation therapy for hepatocellular carcinoma combined with systemic therapy[J]. Electronic Journal of Liver Tumor, 2022, 9(4): 15-19.

参考文献

[1] LIU D, SONG T.Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China[J]. Biosci Trends, 2021, 15(3): 142-147.
[2] YANG J D, AHMED MOHAMMED H, HARMSEN W S, et al.Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota: A US Population-based Study[J]. J Clin Gastroenterol, 2017, 51(8): 742-748.
[3] AFFO S, YU L X, SCHWABE R F.The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer[J]. Annu Rev Pathol, 2017, 12: 153-186.
[4] FORNER A, GILABERT M, BRUIX J, et al.Treatment of intermediate-stage hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2014, 11(9): 525-535.
[5] RODRIGUEZ-PERALVAREZ M, LUONG T V, ANDREANA L, et al.A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability[J]. Ann Surg Oncol, 2013, 20(1): 325-339.
[6] BROWN Z J, GRETEN T F, HEINRICH B.Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy[J]. Hepatology, 2019, 70(4): 1437-1442.
[7] SAPISOCHIN G, BRUIX J.Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 203-217.
[8] LLOVET J M, SCHWARTZ M, MAZZAFERRO V.Resection and liver transplantation for hepatocellular carcinoma[J]. Semin Liver Dis, 2005, 25(2): 181-200.
[9] DELIS S G, DERVENIS C.Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease[J]. World J Gastroenterol, 2008, 14(22): 3452-3460.
[10] VACLAV T.Surgical treatment of hepatocellular carcinoma[J]. Klin Onkol, 2020, 33(Supplementum 3): 30-33.
[11] ZHOU H, SONG T.Conversion therapy and maintenance therapy for primary hepatocellular carcinoma[J]. Biosci Trends, 2021, 15(3): 155-160.
[12] ESTES C, RAZAVI H, LOOMBA R, et al.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease[J]. Hepatology, 2018, 67(1): 123-133.
[13] ZUCMAN-ROSSI J, VILLANUEVA A, NAULT J C, et al. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma[J]. Gastroenterology, 2015, 149(5): 1226-1239. e4.
[14] JOHNSTON M P, KHAKOO S I.Immunotherapy for hepatocellular carcinoma: Current and future[J]. World J Gastroenterol, 2019, 25(24): 2977-2989.
[15] LIU Z, LIU X, LIANG J, et al.Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects[J]. Front Immunol, 2021, 12: 765101.
[16] SIM H W, KNOX J.Hepatocellular carcinoma in the era of immunotherapy[J]. Curr Probl Cancer, 2018, 42(1): 40-48.
[17] KOREAN LIVER CANCER ASSOCIATION; NATIONAL CANCER CENTER. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma[J]. Gut Liver, 2019, 13(3): 227-299.
[18] MA S, JIAO B, LIU X, et al.Approach to radiation therapy in hepatocellular carcinoma[J]. Cancer Treat Rev, 2010, 36(2): 157-163.
[19] MORNEX F, GIRARD N, BEZIAT C, et al.Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French PhaseⅡ RTF-1 trial[J]. Int J Radiat Oncol Biol Phys, 2006, 66(4): 1152-1158.
[20] SEONG J, LEE I J, SHIM S J, et al.A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea[J]. Liver Int, 2009, 29(2): 147-152.
[21] KOULOULIAS V, MOSA E, GEORGAKOPOULOS J, et al.Three-dimensional conformal radiotherapy for hepatocellular carcinoma in patients unfit for resection, ablation, or chemotherapy: a retrospective study[J]. Sci World J, 2013: 780141.
[22] BUJOLD A, MASSEY C A, KIM J J, et al.Sequential phaseⅠ andⅡ trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma[J]. J Clin Oncol, 2013, 31(13): 1631-1639.
[23] HONG T S, WO J Y, YEAP B Y, et al.Multi-Institutional Phase Ⅱ Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma[J]. J Clin Oncol, 2016, 34(5): 460-468.
[24] YANG J F, LO C H, LEE M S, et al.Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis[J]. Radiat Oncol, 2019, 14(1): 180.
[25] KIM T H, KOH Y H, KIM B H, et al.Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase Ⅲ trial[J]. J Hepatol, 2021, 74(3): 603-612.
[26] SANFORD N N, PURSLEY J, NOE B, et al.Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival[J]. Int J Radiat Oncol Biol Phys, 2019, 105(1): 64-72.
[27] HASAN S, ABEL S, VERMA V, et al.Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation[J]. J Gastrointest Oncol, 2019, 10(5): 999-1009.
[28] JIA Z, JIANG G, TIAN F, et al.A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis[J]. Saudi J Gastroenterol, 2016, 22(5): 353-359.
[29] QASEEM Y, SALEM R.Observing Durable Responses and a Prolonged Survival Tail in Advanced Hepatocellular Carcinoma with Portal Vein Invasion Treated with Y90 Radioembolization[J]. Cardiovasc Intervent Radiol, 2020, 43(9): 1423-1424.
[30] SEAGER M J.Radiation Segmentectomy for Small, Solitary Hepatocellular Carcinoma[J]. Radiol Imaging Cancer, 2021, 3(2): e219006.
[31] LLOVET J M, KELLEY R K, VILLANUEVA A, et al.Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6.
[32] TELLA S H, KOMMALAPATI A, MAHIPAL A.Systemic therapy for advanced hepatocellular carcinoma: targeted therapies[J]. Chin Clin Oncol, 2021, 10(1): 10.
[33] SPERANDIO R C, PESTANA R C, MIYAMURA B V, et al.Hepatocellular Carcinoma Immunotherapy[J]. Annu Rev Med, 2022, 73: 267-278.
[34] KASEB A O, HASANOV E, CAO H S T, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 208-218.
[35] JIANG M, HU Y, LIN G, et al.Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course[J]. Front Oncol, 2022, 12: 906251.
[36] NAIMI A, MOHAMMED R N, RAJI A, et al.Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons[J]. Cell Commun Signal, 2022, 20(1): 44.
[37] ROSSI A J, KHAN T M, SAIF A, et al.Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 Antibody[J]. Ann Surg Oncol, 2022, 29(1): 30-32.
[38] FINN R S, RYOO B Y, MERLE P, et al.Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, PhaseⅢ Trial[J]. J Clin Oncol, 2020, 38(3): 193-202.
[39] YAU T, PARK J W, FINN R S, et al.Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2022, 23(1): 77-90.
[40] ROESSLER D, OCAL O, PHILIPP A B, et al. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study[J]. J Cancer Res Clin Oncol, 2022. Online ahead of print.
[41] REIG M, SANDUZZI-ZAMPARELLI M.Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study[J]. Lancet Oncol, 2022, 23(1): 4-6.
[42] MI H, HO W J, YARCHOAN M, et al.Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma[J]. Front Immunol, 2022, 13: 892250.
[43] WU W C, LIN T Y, CHEN M H, et al.Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience[J]. Invest New Drugs, 2022, 40(4): 789-797.
[44] SONG C W, GLATSTEIN E, MARKS L B, et al.Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell Death[J]. Int J Radiat Oncol Biol Phys, 2021, 110(1): 21-34.
[45] TAI D, LOKE K, GOGNA A, et al.Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(12): 1025-1035.
[46] OCAL O, SCHUTTE K, ZECH C J, et al.Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib[J]. Eur J Nucl Med Mol Imaging, 2022, 49(13): 4716-4726.
[47] HSIEH C H, CHEN Y J, TSAI T H, et al.Robust combination of liver stereotactic body radiotherapy modulates pharmacokinetics of sorafenib toward preferable parameters[J]. Sci Rep, 2020, 10(1): 9575.
[48] CHI K H, LIAO C S, CHANG C C, et al.Angiogenic blockade and radiotherapy in hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2010, 78(1): 188-193.
[49] YOON H I, SONG K J, LEE I J, et al.Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis[J]. Cancer Res Treat, 2016, 48(1): 190-197.
[50] LU Y S, CHOU C H, TZEN K Y, et al.Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2012, 83(2): e181-e189.
[51] LIN Z Z, CHOU C H, CHENG A L, et al.Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption[J]. Int J Cancer, 2014, 135(2): 492-501.
[52] LIU W L, GAO M, TZEN K Y, et al.Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma[J]. Oncotarget, 2014, 5(11): 3662-3672.
[53] HUANG C Y, TAI W T, HSIEH C Y, et al.A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3[J]. Cancer Lett, 2014, 349(2): 136-143.
[54] ZHONG L, WU D, PENG W, et al.Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma[J]. Front Oncol, 2021, 11: 686621.
[55] YOO G S, AHN W G, KIM S Y, et al.Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study[J]. Clin Mol Hepatol, 2021, 27(1): 144-156.
[56] LEE Y H, TAI D, YIP C, et al.Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond[J]. Front Immunol, 2020, 11: 568759.
[57] SATO H, NIIMI A, YASUHARA T, et al.DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells[J]. Nat Commun, 2017, 8(1): 1751.
[58] GOLDSTEIN M, KASTAN M B.The DNA damage response: implications for tumor responses to radiation and chemotherapy[J]. Annu Rev Med, 2015, 66: 129-143.
[59] SHENG H, HUANG Y, XIAO Y, et al.ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma[J]. J Immunother Cancer, 2020, 8(1): e000340.
[60] KARIMIAN A, MIR S M, PARSIAN H, et al.Crosstalk between Phosphoinositide 3-kinase/Akt signaling pathway with DNA damage response and oxidative stress in cancer[J]. J Cell Biochem, 2019, 120(6): 10248-10272.
[61] ZHANG Y, XIE C, LI A, et al.PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway[J]. Am J Transl Res, 2019, 11(8): 5134-5149.